Overview

Recombinant Human Relaxin for the Treatment of Decompensated CHF

Status:
Terminated
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
Two doses of relaxin will be compared to placebo for the treatment of patients with decompensated CHF
Phase:
Phase 2
Details
Lead Sponsor:
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Treatments:
Methocarbamol